Navigation Links
Rat Paraffin Neuronal Tissue Microarray from Zyagen Laboratories

ProductsRat Paraffin Neuronal Tissue Microarray from Zyagen Laboratories
Company Zyagen Laboratories
Item Rat Paraffin Neuronal Tissue Microarray
Price $380.00
Description Zyagen tissue microarrays are derived from Paraffin embedded tissue blocks, which are subjected to rigorous quality control procedures to ensure the highest quality. Tissues of each array are manually assembled in one block, sectioned at a thickness of 5 microns and mounted on coated slides. Sections are large (3-5 mm in diameter) in comparison to core sections made using Tissue Arrayer. Arrays enable high throughput screening of large number of tissue specimens by immunohistochemistry and in situ hybridization.

Tissues: Cerebellum, Entorhinal cortex, Frontal cortex, Posterior cortex, Hippocampus, Hypothalamus, Olfactory bulb, Pons, Striatum, Medulla, Thalamus, and Spinal cord
Info Zyagen LaboratoriesZyagen Laboratories
10225 Barnes Canyon Road
San Diego, CA 92121
Customer Service: 858-442-0704
Fax Number: 858-546-0736
Web Site: http://www.zyagen.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Mouse Paraffin Digestive Tissue Microarray from Zyagen Laboratories
2. Mouse Paraffin Mixed Tissue Microarray, Panel -3 from Zyagen Laboratories
3. Rat Paraffin Reproductive Tissue Microarray from Zyagen Laboratories
4. Rat Paraffin Digestive Tissue Microarray from Zyagen Laboratories
5. Rat Paraffin Mixed Tissue Microarray, Panel- 2 from Zyagen Laboratories
6. Paraffin Tissue Section Panel - Monkey (Simian) Normal Tissue, Multi-tissue I from BioChain
7. NuParaffin Kit from Exalpha Biologicals, Inc.
8. Mouse Frozen Neuronal Tissue Microarray from Zyagen Laboratories
9. Rat Frozen Neuronal Tissue Microarray from Zyagen Laboratories
10. Anti-Glycine Transporter 2, Neuronal (GLYT2) Polyclonal Antibody, Unconjugated from CHEMICON
11. MaxArray Tissue Array (Animal - Rabbit) from Invitrogen
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2House fly genome reveals expanded immune system 2
... understand extreme sea creaturesExtraordinary creatures who inhabit extreme underwater ... three-year project. These deep-sea communities could reveal an evolutionary ... give us clues to how life could exist onother ... - incredibly hot environments in the deep sea - ...
... how Listeria monocytogenes, which causes a major ... and hide from the body's immune system. They believe ... , The Listeria bacterium, found in ... undercooked and unpasteurized food, causing flu-like symptoms or gastrointestinal ...
... blood pressure-lowering gene into cells and enables that gene to ... to take gene therapy for the disorder a step closer ... a report released online in the Proceedings of the National ... the leading causes of death and disability in adults worldwide," ...
Cached Biology News:Gene discovery sheds light on causes of rare disease, cancer 2Gene therapy to lower blood pressure just enough 2
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6